Nunzia Simona Losito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nunzia Simona Losito has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Gerardo Botti
Scientific Direction, Istituto Nazionale Tumori-Irccs-Fondazione G.Pascale, 80131 Naples, Italy
3 shared publications - Francesca Falcone
Malzoni Research Hospital, Avellino, Italy
2 shared publications - Franco Fulciniti
Clinical Cytopathology Service and Pathology Institute of Locarno, Locarno, Switzerland
2 shared publications - Giuseppe Laurelli
Department of Gynecologic Oncology Surgery, Istituto Nazionale Tumori, IRCSS, "Fondazione G. Pascale", Naples, Italy
2 shared publications - Stefano Greggi
Gynecology Oncology Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, Italy
2 shared publications A. B. Maffione
Anatomy, University of Bari, Medical School, Italy
1 shared publication
Latest Publications
- Open Access
- 3 May 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (5) , eaav3235
USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability
Snail is a target of USP1 that links platinum response to metastasis in ovarian cancer.
- 3 May 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (5) , eaav3235
Open AccessUSP1 links platinum resistance to cancer cell dissemination by regulating Snail stability
Snail is a target of USP1 that links platinum response to metastasis in ovarian cancer.
- 29 November 2018
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 48 (2) , 108-114
Overexpression of ADAR 1 into the cytoplasm correlates with a better prognosis of patients with oral squamous cells carcinoma
Background: ADAR1 is an enzymatic protein, which catalyzes a RNA editing reaction by converting Adenosine to Inosine, and its expression has been found to be dysregulated in many cancer types. The aim of this study was to analyze the expression of ADAR1 in oral squamous cells carcinoma. Methods: In order to analyze the ADAR1 mRNA expression, data from The Cancer Genome Atlas (TCGA) database were downloaded and analyzed. In addition, immunohistochemistry analysis was performed on an institutional database including 46 samples of oral squamous cell carcinoma in a tissue microarray (TMA). Results: No statistically significant correlation linked the mRNA ADAR1 expression to any clinic-pathological variables in the TCGA database. Immunohistochemistry analysis of ADAR1 showed different expressions between normal mucosa and tumor tissue. Focusing on the subcellular localization, the nuclear expression of ADAR1 correlated with higher grading of differentiation (ρ = 0.442; P-value = 0.002); the general expression of ADAR1 either in cytoplasm or in nuclei, correlated with the Gender of patients (Cytoplasm expression: ρ = −0.295; P-value = 0.049; while for nuclear expression: ρ = +0.374; P = 0.011); cytosol expression resulted to be an independent protective prognostic factor (HR = 0.047; C.I. 95% 0.007-0.321; P-value = 0.002). Conclusion: Higher expression of ADAR1 into the cytoplasm resulted to be an independent prognostic factor. In order to understand ADAR1 role in cancer, further studies should be performed, in bigger cohort and under a bio-molecular point of view.
- 29 November 2018
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 48 (2) , 108-114
Overexpression of ADAR 1 into the cytoplasm correlates with a better prognosis of patients with oral squamous cells carcinoma
Background: ADAR1 is an enzymatic protein, which catalyzes a RNA editing reaction by converting Adenosine to Inosine, and its expression has been found to be dysregulated in many cancer types. The aim of this study was to analyze the expression of ADAR1 in oral squamous cells carcinoma. Methods: In order to analyze the ADAR1 mRNA expression, data from The Cancer Genome Atlas (TCGA) database were downloaded and analyzed. In addition, immunohistochemistry analysis was performed on an institutional database including 46 samples of oral squamous cell carcinoma in a tissue microarray (TMA). Results: No statistically significant correlation linked the mRNA ADAR1 expression to any clinic-pathological variables in the TCGA database. Immunohistochemistry analysis of ADAR1 showed different expressions between normal mucosa and tumor tissue. Focusing on the subcellular localization, the nuclear expression of ADAR1 correlated with higher grading of differentiation (ρ = 0.442; P-value = 0.002); the general expression of ADAR1 either in cytoplasm or in nuclei, correlated with the Gender of patients (Cytoplasm expression: ρ = −0.295; P-value = 0.049; while for nuclear expression: ρ = +0.374; P = 0.011); cytosol expression resulted to be an independent protective prognostic factor (HR = 0.047; C.I. 95% 0.007-0.321; P-value = 0.002). Conclusion: Higher expression of ADAR1 into the cytoplasm resulted to be an independent prognostic factor. In order to understand ADAR1 role in cancer, further studies should be performed, in bigger cohort and under a bio-molecular point of view.
- 1 September 2016
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 42 (9) , S157-S158
378. Long-term oncologic and reproductive outcomes in young women with early endometrial cancer conservatively treated: An update from an institutional prospective study
- 1 September 2016
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 42 (9) , S157-S158
378. Long-term oncologic and reproductive outcomes in young women with early endometrial cancer conservatively treated: An update from an institutional prospective study
- 21 May 2015
- Published by Wiley in Diagnostic Cytopathology
- Vol. 43 (8) , 654-658
Brooke‐Spiegler syndrome presenting multiple concurrent cutaneous and parotid gland neoplasms: Cytologic findings on fine‐needle sample and description of a novel mutation of the CYLD gene
Multiple dermal cylindromas and membranous basal cell adenoma of parotid gland in a 67‐year‐old woman with Brooke‐Spiegler syndrome (BSS) were examined by fine‐needle cytology. Histology, immunochemistry, and CYLD germline mutation testing were also performed. Cytomorphology and immunochemistry of the two lesions showed basaloid neoplasms, remarkably similar, composed by proliferating epithelial cells of basal type accompanied by a smaller proportion of myoepithelial cells. CYLD gene showed a novel germline splice acceptor site mutation (c.2042‐1G>C) with skipping of the entire exon 15. The occurrence of analogous tumors, dermal cylindromas, and membranous basal cell adenoma of the parotid gland, in the same patient may result from the action of a single gene on ontogenetically similar stem cells. Therefore, patients with BSS should be offered a genetic counselling for an early and correct diagnosis. Diagn. Cytopathol. 2015;43:654–658.
- 21 May 2015
- Published by Wiley in Diagnostic Cytopathology
- Vol. 43 (8) , 654-658
Brooke‐Spiegler syndrome presenting multiple concurrent cutaneous and parotid gland neoplasms: Cytologic findings on fine‐needle sample and description of a novel mutation of the CYLD gene
Multiple dermal cylindromas and membranous basal cell adenoma of parotid gland in a 67‐year‐old woman with Brooke‐Spiegler syndrome (BSS) were examined by fine‐needle cytology. Histology, immunochemistry, and CYLD germline mutation testing were also performed. Cytomorphology and immunochemistry of the two lesions showed basaloid neoplasms, remarkably similar, composed by proliferating epithelial cells of basal type accompanied by a smaller proportion of myoepithelial cells. CYLD gene showed a novel germline splice acceptor site mutation (c.2042‐1G>C) with skipping of the entire exon 15. The occurrence of analogous tumors, dermal cylindromas, and membranous basal cell adenoma of the parotid gland, in the same patient may result from the action of a single gene on ontogenetically similar stem cells. Therefore, patients with BSS should be offered a genetic counselling for an early and correct diagnosis. Diagn. Cytopathol. 2015;43:654–658.
- 1 March 2015
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 39 (3) , 338-348
Clear Cell Myoepithelial Carcinoma of Salivary Glands Showing EWSR1 Rearrangement
This study examines the presence of the EWSR1 rearrangement in a variety of clear cell salivary gland carcinomas with myoepithelial differentiation. A total of 94 salivary gland carcinomas with a prominent clear cell component included 51 cases of clear cell myoepithelial carcinomas de novo (CCMC), 21 cases of CCMCs ex pleomorphic adenoma (CCMCexPA), 11 cases of epithelial-myoepithelial carcinoma (EMC), 6 cases of EMC with solid clear cell overgrowth, and 5 cases of hyalinizing clear cell carcinoma of minor salivary glands. In addition, 10 cases of myoepithelial carcinomas devoid of clear cell change and 12 cases of benign myoepithelioma were included as well. All the tumors in this spectrum were reviewed, reclassified, and tested by fluorescence in situ hybridization (FISH) for the EWSR1 rearrangement using the Probe Vysis EWSR1 Break Apart FISH Probe Kit. The EWSR1 rearrangement was detected in 20 of 51 (39%) cases of CCMC, in 5 of 21 (24%) cases of CCMCexPA, in 1 of 11 (9%) cases of EMC, and in 4 of 5 (80%) cases of hyalinizing clear cell carcinoma. The 25 EWSR1-rearranged CCMCs and CCMCexPAs shared similar histomorphology. They were arranged in nodules composed of compact nests of large polyhedral cells with abundant clear cytoplasm. Necrosis, areas of squamous metaplasia, and hyalinization were frequent features. Immunohistochemically, the tumors expressed p63 (96%), cytokeratin CK14 (96%), and S100 protein (88%). MIB1 index varied from 10% to 100%, with most cases in the 20% to 40% range. Clinical follow-up information was available in 21 cases (84%) and ranged from 3 months to 15 years (mean 5.2 y); 4 patients were lost to follow-up. Ten patients are alive with no evidence of recurrent or metastatic disease in the follow-up period from 3 months to 15 years (mean 5 y), 3 patients are alive with recurrent and metastatic disease, and 8 died of disseminated cancer 9 months to 16 years after diagnosis (mean 6 y). Lymph node metastasis appeared in 5 patients within 5 months to 4 years after diagnosis (mean 22 mo), distant metastases were noted in 7 patients with invasion of orbit (2 cases), and in 1 case each metastasis to the neck soft tissues, liver, lungs, mediastinum, and thoracic vertebra was noted. We describe for the first time EWSR1 gene rearrangement in a subset of myoepithelial carcinomas arising in minor and major salivary glands. The EWSR1-rearranged CCMC represents a distinctive aggressive variant composed predominantly of clear cells with frequent necrosis. Most EWSR1-rearranged CCMCs of salivary glands are characterized by poor clinical outcomes.
- 1 March 2015
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 39 (3) , 338-348
Clear Cell Myoepithelial Carcinoma of Salivary Glands Showing EWSR1 Rearrangement
This study examines the presence of the EWSR1 rearrangement in a variety of clear cell salivary gland carcinomas with myoepithelial differentiation. A total of 94 salivary gland carcinomas with a prominent clear cell component included 51 cases of clear cell myoepithelial carcinomas de novo (CCMC), 21 cases of CCMCs ex pleomorphic adenoma (CCMCexPA), 11 cases of epithelial-myoepithelial carcinoma (EMC), 6 cases of EMC with solid clear cell overgrowth, and 5 cases of hyalinizing clear cell carcinoma of minor salivary glands. In addition, 10 cases of myoepithelial carcinomas devoid of clear cell change and 12 cases of benign myoepithelioma were included as well. All the tumors in this spectrum were reviewed, reclassified, and tested by fluorescence in situ hybridization (FISH) for the EWSR1 rearrangement using the Probe Vysis EWSR1 Break Apart FISH Probe Kit. The EWSR1 rearrangement was detected in 20 of 51 (39%) cases of CCMC, in 5 of 21 (24%) cases of CCMCexPA, in 1 of 11 (9%) cases of EMC, and in 4 of 5 (80%) cases of hyalinizing clear cell carcinoma. The 25 EWSR1-rearranged CCMCs and CCMCexPAs shared similar histomorphology. They were arranged in nodules composed of compact nests of large polyhedral cells with abundant clear cytoplasm. Necrosis, areas of squamous metaplasia, and hyalinization were frequent features. Immunohistochemically, the tumors expressed p63 (96%), cytokeratin CK14 (96%), and S100 protein (88%). MIB1 index varied from 10% to 100%, with most cases in the 20% to 40% range. Clinical follow-up information was available in 21 cases (84%) and ranged from 3 months to 15 years (mean 5.2 y); 4 patients were lost to follow-up. Ten patients are alive with no evidence of recurrent or metastatic disease in the follow-up period from 3 months to 15 years (mean 5 y), 3 patients are alive with recurrent and metastatic disease, and 8 died of disseminated cancer 9 months to 16 years after diagnosis (mean 6 y). Lymph node metastasis appeared in 5 patients within 5 months to 4 years after diagnosis (mean 22 mo), distant metastases were noted in 7 patients with invasion of orbit (2 cases), and in 1 case each metastasis to the neck soft tissues, liver, lungs, mediastinum, and thoracic vertebra was noted. We describe for the first time EWSR1 gene rearrangement in a subset of myoepithelial carcinomas arising in minor and major salivary glands. The EWSR1-rearranged CCMC represents a distinctive aggressive variant composed predominantly of clear cells with frequent necrosis. Most EWSR1-rearranged CCMCs of salivary glands are characterized by poor clinical outcomes.
- Open Access
- 20 January 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (7) , 5310-5323
PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration
PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration
- 20 January 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (7) , 5310-5323
Open AccessPATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration
PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration
- 13 August 2009
- Published by Springer Nature in Virchows Archiv
- Vol. 455 (3) , 245-251
Adhesion molecules and p16 expression in endocervical adenocarcinoma
An immunohistochemical (IHC) study has been conducted on 34 cases of untreated endocervical adenocarcinomas collected among three institutions (Ospedale S. Andrea, Rome; Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples; and Clinica Malzoni, Avellino). The E-cadherin and α- and β-catenin complex status has been investigated along with p16INK4a in all studied cases with the aim to study whether the pattern of expression of the cadherin–catenin complex could be causally related to the expression of P16INK4a protein. Results were evaluated for statistical significance by a non-parametric test (Kruskal–Wallis). Endocervical adenocarcinomas as a group were uniformly expressing p16INK4a except for two cases, and all lesions displayed downregulation of the cadherin–catenin complex, without demonstrating statistically significant differences among the different histotypes. The lack of nuclear accumulation of β-catenin found in this group of lesions probably implies that no alteration of the β-catenin/Wnt metabolic pathway is present in endocervical adenocarcinoma, as opposed to what is found in the literature for squamous carcinoma of the cervix. The diffuse expression of p16INK4a protein in this group of neoplasms stresses the important role of high-risk human papillomavirus infection in neoplastic causation possibly via the viral E7-mediated inactivation of pRB tumor-suppressor protein and also underlines the useful role of p16INK4a immunostaining in the diagnostic algorithm of endocervical adenocarcinomas. In consideration of these findings, investigation of downstream β-catenin genes c-myc and cyclin D1 is sought as possibly contributive in the molecular pathogenesis of endocervical adenocarcinoma.
- 13 August 2009
- Published by Springer Nature in Virchows Archiv
- Vol. 455 (3) , 245-251
Adhesion molecules and p16 expression in endocervical adenocarcinoma
An immunohistochemical (IHC) study has been conducted on 34 cases of untreated endocervical adenocarcinomas collected among three institutions (Ospedale S. Andrea, Rome; Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples; and Clinica Malzoni, Avellino). The E-cadherin and α- and β-catenin complex status has been investigated along with p16INK4a in all studied cases with the aim to study whether the pattern of expression of the cadherin–catenin complex could be causally related to the expression of P16INK4a protein. Results were evaluated for statistical significance by a non-parametric test (Kruskal–Wallis). Endocervical adenocarcinomas as a group were uniformly expressing p16INK4a except for two cases, and all lesions displayed downregulation of the cadherin–catenin complex, without demonstrating statistically significant differences among the different histotypes. The lack of nuclear accumulation of β-catenin found in this group of lesions probably implies that no alteration of the β-catenin/Wnt metabolic pathway is present in endocervical adenocarcinoma, as opposed to what is found in the literature for squamous carcinoma of the cervix. The diffuse expression of p16INK4a protein in this group of neoplasms stresses the important role of high-risk human papillomavirus infection in neoplastic causation possibly via the viral E7-mediated inactivation of pRB tumor-suppressor protein and also underlines the useful role of p16INK4a immunostaining in the diagnostic algorithm of endocervical adenocarcinomas. In consideration of these findings, investigation of downstream β-catenin genes c-myc and cyclin D1 is sought as possibly contributive in the molecular pathogenesis of endocervical adenocarcinoma.
- 1 January 2000
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 22 (1) , 1-18
In VivoEffects of Recombinant-Interferon-β1bTreatment on Polymorphonuclear Cell and Monocyte Functions and On T-Cell-Mediated Antibacterial Activity in Patients with Relapsing-Remitting Multiple Sclerosis
Treatment with Interferon (IFN)-β has been proposed as a therapeutic approach in multiple sclerosis (MS) patients, mostly in view of its immunomodulating actions. At the same time, evidence has been provided that MS patients exhibit polymorphonuclear cell (PMN) deficits, which can explain the increased susceptibility to infections in these subjects. Here, in 28 patients with relapsingremitting (RR) MS under treatment with recombinant (r)-IFN-β PMN polarization and PMN and monocyte (MO) phagocytosis and killing, as well as T-cell mediated antibacterial activity, were evaluated before treatment and over a period of nine months of treatment. Our results point out an enhanced rate of polarization (both “spontaneous” or N-formyl-methionyl-leucyl-phenylalanine-induced) in MS patients. After r-IFN-β1b treatment the polarization rate was further increased. On the contrary, PMN and MO phagocytosis and killing were depressed in comparison to controls and values were further reduced by r-IFN-β1b treatment. In patients T-cell mediated antibacterial activity was decreased at TO and dramatically dropped in the course of r-IFN-β1b therapy.
- 1 January 2000
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 22 (1) , 1-18
In VivoEffects of Recombinant-Interferon-β1bTreatment on Polymorphonuclear Cell and Monocyte Functions and On T-Cell-Mediated Antibacterial Activity in Patients with Relapsing-Remitting Multiple Sclerosis
Treatment with Interferon (IFN)-β has been proposed as a therapeutic approach in multiple sclerosis (MS) patients, mostly in view of its immunomodulating actions. At the same time, evidence has been provided that MS patients exhibit polymorphonuclear cell (PMN) deficits, which can explain the increased susceptibility to infections in these subjects. Here, in 28 patients with relapsingremitting (RR) MS under treatment with recombinant (r)-IFN-β PMN polarization and PMN and monocyte (MO) phagocytosis and killing, as well as T-cell mediated antibacterial activity, were evaluated before treatment and over a period of nine months of treatment. Our results point out an enhanced rate of polarization (both “spontaneous” or N-formyl-methionyl-leucyl-phenylalanine-induced) in MS patients. After r-IFN-β1b treatment the polarization rate was further increased. On the contrary, PMN and MO phagocytosis and killing were depressed in comparison to controls and values were further reduced by r-IFN-β1b treatment. In patients T-cell mediated antibacterial activity was decreased at TO and dramatically dropped in the course of r-IFN-β1b therapy.
- 31 March 1998
- Published by Elsevier in Robotics and Autonomous Systems
- Vol. 23 (1-2) , 29-36
JERICO: A demonstration of autonomous robotic servicing on the Mir space station
- 31 March 1998
- Published by Elsevier in Robotics and Autonomous Systems
- Vol. 23 (1-2) , 29-36
JERICO: A demonstration of autonomous robotic servicing on the Mir space station